Immune System News and Research

RSS

Boston College biologist receives $2.7M NIH grant to continue HIV and AIDS research

Boston College biologist Ken Williams, whose research focuses on the role of immunological cells in a range of illnesses that strike people living with HIV and AIDS, has been awarded a five-year, $2.7 million grant from the NIH's National Institute of Neurological Disorders and Stroke.

12 Feb 2013

LASAG trial for severe influenza initiated

...

12 Feb 2013

Growth factor aids mandible reconstruction

Surgeons have used recombinant human bone morphogenetic protein-2 to successfully restore mandibulectomy defects with few adverse effects.

12 Feb 2013

Metastatic renal cell carcinoma (mRCC) therapy: an interview with Charles A. Nicolette, Ph.D., CSO of Argos Therapeutics

Metastatic renal cell carcinoma is a devastating disease. There are roughly 20-25,000 new cases per year in the United States and it is increasing for some reason.

12 Feb 2013

Berkeley Lab researchers resolve EGFR activation mystery

Researchers with Lawrence Berkeley National Laboratory (Berkeley Lab) and the University of California (UC) Berkeley have provided important new details into the activation of the epidermal growth factor receptor (EGFR), a cell surface protein that has been strongly linked to a large number of cancers and is a major target of cancer therapies.

12 Feb 2013

Individualized flu immune responses revealed by high-throughput sequencing

Researchers have shown that it is possible to create personalized, individual-specific measurements of the antibody repertoire in response to influenza vaccination using high-throughput DNA sequencing technology.

11 Feb 2013

CD8+ Tregs can remove pathogenic T cell subsets and inhibit progression of RA

Rheumatoid arthritis (RA) is an autoimmune disorder in which immune cells attack the joints, causing inflammation, swelling, and erosion. Specific sets of immune cells, known as T cells, are responsible for inducing disease. In this issue of the Journal of Clinical Investigation, researchers led by Harvey Cantor at Harvard University analyzed the contributions of different subsets of T cells to an RA-like condition in mice.

11 Feb 2013

Excessive ERK activation underlies lymphatic defects in RASopathies

The RAS pathway is a cellular signaling pathway that regulates growth and development in humans. RASopathies are a group of diseases characterized by defects in RAS signaling. Many patients with RASopathies present with defects in the lymphatic system, which removes excess fluid from tissues, absorbs fats from the digestive system, and transports immune cells.

11 Feb 2013

Infusions of regulatory T cells turn off autoimmune attack on joints

Farber Cancer Institute scientists have demonstrated a new strategy for treating autoimmune disease that successfully blocked the development of rheumatoid arthritis in a mouse model. They say it holds promise for improved treatment of arthritis and other autoimmune disorders in people.

10 Feb 2013

Combination of two antibodies prevents growth and spread of triple-negative breast tumors

Cancer drugs of the new, molecular generation destroy malignant breast tumors in a targeted manner: They block characteristic molecules on tumor cells - receptors for the hormones estrogen or progesterone, or a co-receptor, called HER2, that binds to many growth factors. But about one in every six breast tumors has none of these receptors. Such cancers, called triple-negative, are particularly aggressive and notoriously difficult to treat.

10 Feb 2013

Virginia Tech researchers reveal how 'bad' gut bacteria may help control diabetes

A stomach bacterium believed to cause health problems such as gastritis, ulcers, and gastric cancer may play a dual role by balancing the stomach's ecosystem and controlling body weight and glucose tolerance, according to immunologists at the Virginia Bioinformatics Institute of Virginia Tech.

10 Feb 2013

Research sheds light on how E. coli thrive in the intestine of people with IBD

Scientists have long puzzled over why "bad" bacteria such as E. coli can thrive in the guts of those with inflammatory bowel disease (IBD), causing serious diarrhea. Now UC Davis researchers have discovered the answer-one that may be the first step toward finding new and better treatments for IBD.

10 Feb 2013

Reprogrammed human skin cells highly effective in treating myelin disorders

A study out today in the journal Cell Stem Cell shows that human brain cells created by reprogramming skin cells are highly effective in treating myelin disorders, a family of diseases that includes multiple sclerosis and rare childhood disorders called pediatric leukodystrophies.

10 Feb 2013

Celgene's Pomalyst receives FDA approval for treatment of multiple myeloma

The U.S. Food and Drug Administration today approved Pomalyst (pomalidomide) to treat patients with multiple myeloma whose disease progressed after being treated with other cancer drugs.

10 Feb 2013

TIC10 may improve usefulness of TRAIL protein in cancer therapy

A compound that stimulates the production of a tumor-fighting protein may improve the usefulness of the protein in cancer therapy, according to a team of researchers.

9 Feb 2013

Milk thistle constituent shows promising skin protection properties

Silibinin, a key component of milk thistle seeds, can help protect against skin damage caused by ultraviolet B radiation, show study findings published in Molecular Carcinogenesis.

8 Feb 2013

Researchers identify an exceptional mouse model of schizophrenia

Researchers at the Institute for Comprehensive Medical Science, Fujita Health University and the National Institute for Physiological Sciences, Japan, along with colleagues from 9 other institutions, have identified an exceptional mouse model of schizophrenia.

7 Feb 2013

Drug-carrying nanoparticles have another hurdle to overcome - escaping the bloodstream

Many medically minded researchers are in hot pursuit of designs that will allow drug-carrying nanoparticles to navigate tissues and the interiors of cells, but University of Michigan engineers have discovered that these particles have another hurdle to overcome: escaping the bloodstream.

7 Feb 2013

First new TB vaccine in century fails initial testing

The first of a series of new vaccines that have been developed to combat tuberculosis failed to show efficacy compared with placebo in South African infants, show results from a phase II trial.

7 Feb 2013